pSivida Corp.(NASDAQ : PSDV)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Loading PSDV News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-3.48%||80.47||1.8%||$677.67m|
|ANAC||Anacor Pharmaceuticals, Inc.||-0.14%||99.06||15.2%||$320.35m|
|REGN||Regeneron Pharmaceuticals, Inc.||-4.95%||339.48||3.1%||$301.85m|
|ALXN||Alexion Pharmaceuticals, Inc.||-8.56%||112.99||2.5%||$274.13m|
|VRTX||Vertex Pharmaceuticals Incorporated||-7.14%||81.90||2.6%||$124.14m|
|BMRN||BioMarin Pharmaceutical Inc.||-7.94%||77.01||4.0%||$117.35m|
|SRPT||Sarepta Therapeutics, Inc.||3.58%||18.52||49.4%||$116.18m|
|CPXX||Celator Pharmaceuticals, Inc.||0.13%||30.19||8.5%||$107.30m|
|A||Agilent Technologies, Inc.||-5.48%||44.12||1.0%||$94.74m|
|IONS||Ionis Pharmaceuticals, Inc.||-6.91%||21.97||8.6%||$94.46m|
pSivida Corp. develops tiny, sustained-release products, which are designed to deliver drugs and biologics at a controlled and steady rate for weeks, months or years. The company through its technology platforms Duraser and BioSilico is focused on treatment of chronic diseases of the back of the eye and are also exploring applications outside ophthalmology. It is also developing a bioerodible, injectable micro-insert delivering latanoprost to treat glaucoma and ocular hypertension. pSivida was founded by Roger Aston in March 2008 and is headquartered in Waterson, MA.